Compared with Shanghai Hehuang Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Heji Huangpu Traditional Chinese Medicine, Hehuang Jianbao Health Products Co., Ltd., a subsidiary of Hehuang China Medical Technology Co., Ltd. (hereinafter referred to as "Hehuang China Medicine"), which is also Li Jiacheng, has a much lower profile.
However, in October this year, Hehuang China Pharmaceutical announced that it would cooperate with HainCeretial, one of the American children's organic food giants, and the infant health food produced by the joint venture would be labeled with the trademarks of Hwang Jianbao's Smart Smart, while Hehuang Jianbao would expand more maternal and infant health products in the coming years; Two months later, he and Huang Jianbao launched a large-scale activity called "Maternity Care Plan", which was supported by Guangzhou Women's Federation, Guangdong Association for Better Birth and Child Care and other institutions. This series of big moves seems to show that Hehuang China Pharmaceutical, which plays a leading role in the pharmaceutical business, will also make efforts to the maternal and infant health care market, is that right? What is the impetus? How will the pharmaceutical business develop next
In the face of many questions, Christian Hogg, Executive Director and CEO of Hehuang China Medical Technology Co., Ltd., who was present at the launching ceremony of the "Maternity Care Plan", received an exclusive interview with reporters.
● Talk about health care business
The reporter obtained some data from Hehuang China Medicine: statistics show that since 2000, China's infant and child economy has been running at a high speed with an annual growth rate of more than 30%. At present, China has become the second largest consumer of infant and child products after the United States; This year, according to the authoritative calculation of the Infant and Child Industry Association, at present, the consumption of infants and children in China accounts for 30% of the total household expenditure. At present, the economic market size of infants and children in China is 750 billion yuan, and the scale in 2010 can reach 100 billion yuan. It is not difficult to find that, from the perspective of Hehuang China Pharmaceutical, China's infant and child health care market has entered a golden period of development.
"Melamine" brings about industry reshuffle, hoping to expand domestic market
He Jun: Affected by melamine and other incidents, the markets of children's and baby food and health food began to adjust and reshuffle. HainCelestial's organic baby products sales ranked first in the US local market, and it is also one of the most famous enterprises in the field of global baby products. We hope that through the joint venture with HainCelestial, we can bring organic baby and children's products produced all over the world to the Chinese market. The domestic market has great potential.
The time is coming to accelerate the development of health care products business
He Jun: Hehuang China Pharmaceutical has been established in the pharmaceutical sector for a long time and has a large scale. There are three joint ventures, namely Hehuang Jianbao Health Products Co., Ltd., Shanghai Hehuang Pharmaceutical Co., Ltd., and Guangzhou Baiyunshan Heji Huangpu Traditional Chinese Medicine. In terms of health care products, we hope to establish a rational and benign growth market. With the economic development, the consumption level and physiological quality of Chinese consumers demand more and more health products. This year, with the development of the company, the development speed will continue to accelerate. We will introduce products with reasonable cost performance into China, including organic milk powder.
● Talk about pharmaceutical business
Traditional Chinese medicine has always been the focus of Hehuang China's pharmaceutical development and also the main business. Shanghai Hehuang Pharmaceutical Co., Ltd. and Guangzhou Baiyunshan Heji Huangpu Traditional Chinese Medicine are very active in both publicity and technical development, because they are still in the investment period, but according to the public performance report data, Hehuang China's medicine has been losing money from its listing in 2006 to the first half of 2009.
2009 interim performance report has turned losses into profits
He Jun: It is now in the investment period, but there are positive benefits. For example, our research and development institutions in Shanghai do research and development of the immune system, and extract the effective substances of traditional Chinese medicine. Now there are positive and encouraging clinical data that enable us to continue to develop. The interim performance report of 2009 has turned losses into profits, developing in a positive direction. According to the sales calculation, the three subordinate companies of Hehuang China Pharmaceutical last year increased by 23% compared with the previous year, while the profits increased by more than 10%. The overall performance of listed companies is good, and the total sales last year was about 1.4 billion yuan.
It is not only used for traditional Chinese medicine, but also for personal care products
He Jun: When it comes to the business of traditional Chinese medicine, in addition to joint ventures in Shanghai and Guangzhou, as well as research and development, we also do consumer goods. We supply Watsons, which belongs to Hutchison Whampoa Group, with our own Chinese herbal medicine personal care products and cosmetics, and sell them through Watsons' retail stores in Europe. In addition, the company is currently actively looking for new investment and merger targets related to traditional Chinese medicine.
● Talk about future development
The new medical reform will benefit the market, and more medical and health care products will be launched next year
He Jun: In the context of the new medical reform, we think it is very positive. It is expected that the Chinese pharmaceutical market will develop more and more healthily, and the pharmaceutical industry will also get better and better. In terms of medicine and health care next year, we will bring more products with reasonable cost performance to Chinese consumers.